STOCK TITAN
  1. Home
  2. Sec-filings
  3. CNO
  4. [Form 4] CNO Financial Group, Inc. Insider Trading Activity

CNO COO sells 14,539 shares after option exercise

CNO’s chief operations officer exercised options and, under a Rule 10b5-1 plan, sold 14,539 common shares in late August and early September 2026.

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CNO Financial Group, Inc. (CNO) chief operations officer Jeanne L. Linnenbringer reported an option exercise and related stock sales. On August 31, 2026, she exercised employee stock options for 5,010 shares of common stock at an exercise price of $23.33 per share, from options that had vested in 2020 and 2021, and sold those 5,010 shares plus an additional 1,550 shares at weighted average prices around $54.99. She then sold 4,060 shares on September 1, 2026 at a weighted average price of $54.73 and 3,919 shares on September 2, 2026 at a weighted average price of $55.11, for total reported sales of 14,539 shares. All reported sales were made in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Linnenbringer Jeanne L.
Role Chief Operations Officer
Sold 14,539 shs ($799K)
Approx. gross sale proceeds $799K
Approx. exercise cost $117K
Type Security Shares Price Value
Sale Common Stock F1, F4 3,919 $55.1109 $216K
Sale Common Stock F1, F3 4,060 $54.7308 $222K
Exercise Employee Stock Option (Right to Buy) F5 5,010 $0.00 $0.00
Sale Common Stock F1, F2 1,550 $54.9846 $85K
Exercise Common Stock 5,010 $23.33 $117K
Sale Common Stock F1, F2 5,010 $54.9879 $275K
Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 26,209 shares (Direct)
Footnotes (5)
  1. F1. Shares sold pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.
  2. F2. Reflects the weighted average sale price. For each of these two transactions, shares were sold at prices ranging from $54.855 per share to $55.36 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
  3. F3. Reflects the weighted average sale price. Shares were sold at prices ranging from $54.415 per share to $55.10 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
  4. F4. Reflects the weighted average sale price. Shares were sold at prices ranging from $54.56 per share to $55.48 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
  5. F5. One-half of the stock options vested and became exercisable on February 21, 2020, and one-half vested and became exercisable on February 21, 2021.
Total shares sold 14,539 shares Common stock sales reported between August 31 and September 2, 2026
Shares sold on August 31, 2026 6,560 shares Common stock sold in open-market transactions on August 31, 2026
Shares sold on September 1, 2026 4,060 shares Common stock sold in open-market transactions on September 1, 2026
Shares sold on September 2, 2026 3,919 shares Common stock sold in open-market transactions on September 2, 2026
Weighted average sale price on August 31, 2026 $54.98 per share Common stock sales with prices ranging from $54.855 to $55.36 per share
Weighted average sale price on September 1, 2026 $54.73 per share Common stock sales with prices ranging from $54.415 to $55.10 per share
Weighted average sale price on September 2, 2026 $55.11 per share Common stock sales with prices ranging from $54.56 to $55.48 per share
Option exercise price $23.33 per share Exercise price for 5,010 shares under employee stock options expiring February 21, 2028
Rule 10b5-1 trading plan regulatory
"Shares sold pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"Reflects the weighted average sale price"
Employee Stock Option (Right to Buy) financial
"Employee Stock Option (Right to Buy) reported as a derivative security"
vested and became exercisable financial
"One-half of the stock options vested and became exercisable on February 21, 2020"

FAQ

What insider transactions did CNO (CNO) report for Jeanne L. Linnenbringer?
Jeanne L. Linnenbringer, chief operations officer of CNO, reported exercising employee stock options for 5,010 shares of common stock and selling a total of 14,539 shares in open-market transactions between August 31 and September 2, 2026, under a Rule 10b5-1 trading plan.

How many CNO (CNO) shares did the executive sell and over what dates?
The executive reported sales totaling 14,539 shares of CNO common stock. These included 6,560 shares sold on August 31, 2026, 4,060 shares on September 1, 2026, and 3,919 shares on September 2, 2026, all in open-market transactions.

At what prices were the reported CNO (CNO) share sales executed?
The filing reports weighted average sale prices. On August 31, 2026, shares were sold around $54.98 per share; on September 1, 2026, around $54.73 per share; and on September 2, 2026, around $55.11 per share, with actual sale prices within stated ranges around these averages.

What were the details of the CNO (CNO) stock option exercise by the executive?
On August 31, 2026, the chief operations officer exercised employee stock options covering 5,010 shares of CNO common stock at an exercise price of $23.33 per share. The options had vested in two equal installments on February 21, 2020 and February 21, 2021.

Were the recent CNO (CNO) insider sales made under a Rule 10b5-1 trading plan?
Yes. The filing states that the shares sold were pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. This means the trades were pre-arranged under that plan rather than decided at the time of each sale.

Does the filing show any remaining options from the exercised CNO (CNO) grant?
For the reported employee stock option covering 5,010 shares with a February 21, 2028 expiration date, the filing shows zero derivative shares remaining following the exercise, indicating that particular option position has been fully exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Linnenbringer Jeanne L.
(Last)(First)(Middle)
C/O CNO FINANCIAL GROUP, INC.
11299 ILLINOIS STREET, SUITE 200
(Street)
CARMEL INDIANA 46032
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CNO Financial Group, Inc. [ CNO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operations Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/31/2026S1,550(1)D$54.9846(2)34,188D
Common Stock08/31/2026M5,010A$23.3339,198D
Common Stock08/31/2026S5,010(1)D$54.9879(2)34,188D
Common Stock09/01/2026S4,060(1)D$54.7308(3)30,128D
Common Stock09/02/2026S3,919(1)D$55.1109(4)26,209D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)$23.3308/31/2026M5,010 (5)02/21/2028Common Stock5,010$00D
Explanation of Responses:
1. Shares sold pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.
2. Reflects the weighted average sale price. For each of these two transactions, shares were sold at prices ranging from $54.855 per share to $55.36 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
3. Reflects the weighted average sale price. Shares were sold at prices ranging from $54.415 per share to $55.10 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
4. Reflects the weighted average sale price. Shares were sold at prices ranging from $54.56 per share to $55.48 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
5. One-half of the stock options vested and became exercisable on February 21, 2020, and one-half vested and became exercisable on February 21, 2021.
Remarks:
Heidi M. Krings, Attorney-in-Fact09/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR